Evidence map›Paper›PMID 31428957›Full record

ArticleIrish journal of medical science2020

May zoledronic acid have negative effects on cognition and muscle performance?

Remzi Bahşi, Volkan Atmiş, Tuğba Turgut, Deniz Mut Sürmeli, Çağlar Coşarderelioğlu, Hande Selvi Öztorun, Ahmet Yalçin, Sevgi Aras, Murat Varli

Abstract read
PubMed Publisher
In one paragraph

Article in Irish journal of medical science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Remzi BahşiDepartment of Geriatrics, Ankara University School of Medicine, Hacettepe, Talatpaşa Blv No:82, Altındağ/Ankara, Turkey. drremzibahsi@gmail.com.ORCID http://orcid.org/0000-0003-1715-6856
Volkan AtmişDepartment of Geriatrics, Ankara University School of Medicine, Hacettepe, Talatpaşa Blv No:82, Altındağ/Ankara, Turkey.
Tuğba TurgutDepartment of Geriatrics, Antalya Education and Research Hospital, Antalya, Turkey.
Deniz Mut SürmeliDepartment of Geriatrics, Ankara University School of Medicine, Hacettepe, Talatpaşa Blv No:82, Altındağ/Ankara, Turkey.
Çağlar CoşarderelioğluDepartment of Geriatrics, Ankara University School of Medicine, Hacettepe, Talatpaşa Blv No:82, Altındağ/Ankara, Turkey.
Hande Selvi ÖztorunDepartment of Geriatrics, Ankara University School of Medicine, Hacettepe, Talatpaşa Blv No:82, Altındağ/Ankara, Turkey.
Ahmet YalçinDepartment of Geriatrics, Ankara University School of Medicine, Hacettepe, Talatpaşa Blv No:82, Altındağ/Ankara, Turkey.
Sevgi ArasDepartment of Geriatrics, Ankara University School of Medicine, Hacettepe, Talatpaşa Blv No:82, Altındağ/Ankara, Turkey.
Murat VarliDepartment of Geriatrics, Ankara University School of Medicine, Hacettepe, Talatpaşa Blv No:82, Altındağ/Ankara, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWe aimed to investigate the effects of zoledronic acid treatment on daily living activities, cognitive functions, depression, muscle strength, and performance.

methodsThe study was conducted retrospectively. Bone mineral densitometry (BMD) values, Katz activities of daily living (ADL), Lawton-Brody instrumental activities of daily living (IADL), mini mental state examination (MMSE), geriatric depression scale (GDS), mini nutritional assessment (MNA), grip strength, and gait speed scores before and 6 months after zoledronic acid administration were compared.

resultsA total of 115 patients were included in the study. There was a significant increase in lumbar total (p < .001), femoral neck (p = .002), and femur total (p = .001) BMD values after zoledronic acid treatment. Significant decrease was found in MMSE (p = .016) and gait speed scores (p = .008) after zoledronic acid treatment, but no significant difference was found in terms of Katz ADL, Lawton-Brody IADL, MNA, GDS, and grip strength (p > .05).

conclusionOur study indicated that zoledronic acid did not affect daily living activities, depression, and muscle strength. Although we have concluded that cognitive and muscle performance may be adversely affected by zoledronic acid treatment.

Indexed as

AgedCognitionFemaleHumansMaleMuscle StrengthRetrospective StudiesZoledronic AcidZoledronic AcidCognitive functionGait speedZoledronic acid

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.